No significant association with survival was observed for patients with PIK3CAmut + pMMR CRC whereas patients with KRASmut + PIK3CAmut + pMMR had a worse CRC‐specific survival, suggesting that KRAS mutations may drive the worse survival observed for this subgroup. This evidence concerns the gene KRAS and colorectal carcinoma.